Thread by @rheum_cat

#ACR22 Monday's RA/comorbidities oral abstract session at 3:00-4:30pm
Preview!

🌟Abs 2215 Solomon, et al.
RCT of n=115 with RA on RTX

❓Does adding TNFi vs DMARD triple therapy reduce arterial inflammation assessed on FDG-PET/CT? 💓⚡

#ACR22

Abs 2215 cont'd

Both tx arms: ⬇arterial inflammation on PET/CT
🔹But, no difference between groups
🔹And, no correlation of arterial inflammation measure with change in DAS28 disease activity

#ACR22

🌟Abs 2216 Truchetet, et al.
French health insurance database

❓Research Q: is JAKi use (vs TNFi use) a/w cancer risk?

#ACR22

Abs 2216 cont'd

With PS-matched cohorts of JAKi and TNFi users, there was no sig association of JAKi use and cancer risk, vs TNFi use (aHR 0.7)

🤔Would methods that account for TNFi➡JAKi make a difference here? pubmed.ncbi.nlm.nih.gov/35505471/

#ACR22

🌟Abs 2217 Razmjou, et al.
RA registry of biologic initiators n=1213

They investigator serum paraoxonase-1 (PON-1) in serum at 0, 6 months as a potential biomarker

👉Improved dz activity correlated with PON-1 levels

#ACR22

🌟Abs 2218 @NamrataRheum

Marketscan 2008-2019
RA on b/tsDMARD n=62K

❓Research Q: Is frailty a/w infx risk?

#ACR22

@NamrataRheum Abs 2218 cont'd

📌To define the exposure of interest (frailty), they used the claims-based frailty index

👉In the MVA, frailty (vs no frailty) was a/w 2.4x risk of infx (HR 1.3 after further comorbidity adjustment)

#ACR22

@NamrataRheum 🌟Abs 2219 @BethIWallace

national VA data 2010-2018
study sample: RA

❓Research Q: is there a dose response for GC use/duration and MACE risk?

#ACR22

@NamrataRheum @BethIWallace 📌Recall @BethIWallace's plenary at #ACR21

https://twitter.com/rheum_cat/status/1457747244132667395?s=20&t=TCB1UpB9XIar2dQauBMrww

@NamrataRheum @BethIWallace 📌Also take a look at this masterful response to a Q&A

https://twitter.com/BethIWallace/status/1460331258886725643?s=20&t=TCB1UpB9XIar2dQauBMrww

@NamrataRheum @BethIWallace Back to Abs 2219

For this study they employed marginal structural models to account for time-varying GC use, and other complex relationships of their variables of interest

📌Throwback to when rheum studies using #MSM were rare:

https://twitter.com/rheum_cat/status/1194363900306874369?s=20&t=TCB1UpB9XIar2dQauBMrww

#ACR22

@NamrataRheum @BethIWallace Abs 2219 cont'd

👉With ⬆days of GC supply in a 6m period, the effect estimates of MACE risk were ⬆
p for trend <0.001 supporting a dose response

Look fwd to more work from @BethIWallace tackling this major issue in RA

#ACR22

@NamrataRheum @BethIWallace 🌟Abs 2220 Kim, et al.
Korean health insurance database

IMID on JAKi n=3947
n=611 had zoster reactivation

#ACR22

@NamrataRheum @BethIWallace Abs 2220 cont'd

👉In MVA, continued JAKi use was not a sig risk factor for zoster recurrence
NB: This is in the context of the analysis being performed among those who had zoster reactivation

#ACR22